home All News open_in_new Full Article

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related […]


today 1 week ago attach_file Other

attach_file Economics
attach_file Events
attach_file Society
attach_file Society
attach_file Other
attach_file Politics
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Science
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 1553234409
Add Watch Country

arrow_drop_down